| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 19 | 2026 | 211 | 4.450 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2026 | 29 | 2.280 |
Why?
|
| Immune System Diseases | 6 | 2026 | 58 | 2.220 |
Why?
|
| STAT3 Transcription Factor | 8 | 2026 | 229 | 2.120 |
Why?
|
| Gain of Function Mutation | 11 | 2022 | 115 | 2.010 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2022 | 160 | 1.830 |
Why?
|
| Janus Kinases | 7 | 2026 | 36 | 1.820 |
Why?
|
| Severe Combined Immunodeficiency | 8 | 2024 | 107 | 1.780 |
Why?
|
| Killer Cells, Natural | 10 | 2025 | 355 | 1.540 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2026 | 1280 | 1.450 |
Why?
|
| STAT1 Transcription Factor | 6 | 2021 | 81 | 1.170 |
Why?
|
| Pyrazoles | 5 | 2020 | 349 | 1.130 |
Why?
|
| Granulomatous Disease, Chronic | 4 | 2020 | 68 | 1.060 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2020 | 167 | 0.740 |
Why?
|
| Wiskott-Aldrich Syndrome | 4 | 2026 | 25 | 0.730 |
Why?
|
| STAT5 Transcription Factor | 3 | 2023 | 93 | 0.680 |
Why?
|
| STAT Transcription Factors | 3 | 2024 | 24 | 0.650 |
Why?
|
| Knee | 1 | 2019 | 21 | 0.600 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2019 | 24 | 0.600 |
Why?
|
| Mutation | 14 | 2023 | 6099 | 0.590 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2019 | 11 | 0.580 |
Why?
|
| Edema | 1 | 2019 | 130 | 0.560 |
Why?
|
| Pneumonia | 1 | 2022 | 341 | 0.560 |
Why?
|
| Humans | 71 | 2026 | 131163 | 0.540 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 387 | 0.530 |
Why?
|
| Lymphoma | 1 | 2020 | 327 | 0.520 |
Why?
|
| Fever | 1 | 2019 | 312 | 0.500 |
Why?
|
| Genetic Testing | 4 | 2022 | 1106 | 0.500 |
Why?
|
| Autoimmune Diseases | 5 | 2023 | 262 | 0.490 |
Why?
|
| Cytokines | 5 | 2022 | 1339 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 570 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 889 | 0.460 |
Why?
|
| Child, Preschool | 21 | 2026 | 15110 | 0.450 |
Why?
|
| Child | 25 | 2026 | 26341 | 0.440 |
Why?
|
| Infant | 17 | 2026 | 13352 | 0.440 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2021 | 895 | 0.430 |
Why?
|
| Transcription Factors | 1 | 2022 | 2406 | 0.380 |
Why?
|
| Adolescent | 21 | 2026 | 20987 | 0.380 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 29 | 0.360 |
Why?
|
| Genome, Human | 1 | 2018 | 1321 | 0.330 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1692 | 0.320 |
Why?
|
| Multifactorial Inheritance | 2 | 2025 | 176 | 0.320 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1939 | 0.320 |
Why?
|
| Lymphopenia | 2 | 2024 | 33 | 0.320 |
Why?
|
| Male | 27 | 2026 | 64957 | 0.310 |
Why?
|
| Signal Transduction | 5 | 2026 | 4686 | 0.300 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 214 | 0.300 |
Why?
|
| Agammaglobulinemia | 2 | 2022 | 42 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2025 | 3436 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 335 | 0.280 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 327 | 0.270 |
Why?
|
| Autoimmunity | 3 | 2022 | 175 | 0.270 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 78 | 0.270 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 694 | 0.270 |
Why?
|
| Female | 29 | 2026 | 70963 | 0.260 |
Why?
|
| Herpesvirus 4, Human | 2 | 2021 | 638 | 0.250 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2017 | 29 | 0.250 |
Why?
|
| Sepsis | 2 | 2021 | 493 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2024 | 500 | 0.240 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 259 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2026 | 354 | 0.240 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 66 | 0.240 |
Why?
|
| Coatomer Protein | 1 | 2016 | 28 | 0.240 |
Why?
|
| Sirolimus | 1 | 2018 | 230 | 0.240 |
Why?
|
| Th1 Cells | 1 | 2017 | 158 | 0.240 |
Why?
|
| Th17 Cells | 1 | 2017 | 101 | 0.230 |
Why?
|
| Young Adult | 12 | 2026 | 10103 | 0.230 |
Why?
|
| Tuberculosis | 1 | 2022 | 550 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 223 | 0.230 |
Why?
|
| Flow Cytometry | 2 | 2026 | 765 | 0.230 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2025 | 10 | 0.220 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 289 | 0.220 |
Why?
|
| Myosin Type V | 1 | 2025 | 9 | 0.220 |
Why?
|
| Interleukin-9 | 1 | 2024 | 7 | 0.220 |
Why?
|
| Infant, Newborn | 9 | 2025 | 8635 | 0.220 |
Why?
|
| Immunophenotyping | 3 | 2018 | 332 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2020 | 272 | 0.220 |
Why?
|
| Immunological Synapses | 2 | 2019 | 32 | 0.210 |
Why?
|
| Penetrance | 1 | 2025 | 107 | 0.210 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 2 | 2023 | 9 | 0.210 |
Why?
|
| Mutation, Missense | 2 | 2020 | 919 | 0.200 |
Why?
|
| Transplantation Conditioning | 3 | 2026 | 328 | 0.200 |
Why?
|
| Nitriles | 4 | 2020 | 163 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 208 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 633 | 0.200 |
Why?
|
| Adult | 16 | 2026 | 31282 | 0.200 |
Why?
|
| Phospholipase C gamma | 1 | 2023 | 27 | 0.200 |
Why?
|
| Eczema | 1 | 2023 | 35 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2023 | 25 | 0.200 |
Why?
|
| Leukopenia | 1 | 2023 | 44 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2023 | 51 | 0.180 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 55 | 0.180 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 7 | 0.170 |
Why?
|
| Galactosemias | 1 | 2021 | 13 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2022 | 344 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2022 | 5063 | 0.170 |
Why?
|
| Pyrimidines | 4 | 2020 | 446 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2024 | 2465 | 0.170 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 50 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1590 | 0.160 |
Why?
|
| Laboratories | 1 | 2021 | 81 | 0.160 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 19 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2025 | 562 | 0.160 |
Why?
|
| France | 1 | 2020 | 90 | 0.160 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1722 | 0.160 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 32 | 0.160 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2020 | 30 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 229 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 157 | 0.150 |
Why?
|
| Mycobacterium avium Complex | 1 | 2019 | 20 | 0.150 |
Why?
|
| Animals | 6 | 2026 | 33912 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 158 | 0.150 |
Why?
|
| Heterozygote | 3 | 2018 | 737 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2020 | 195 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 197 | 0.140 |
Why?
|
| Homozygote | 1 | 2020 | 533 | 0.140 |
Why?
|
| Thymus Gland | 2 | 2023 | 104 | 0.140 |
Why?
|
| Actins | 1 | 2020 | 321 | 0.140 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 2 | 2018 | 5 | 0.140 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 37 | 0.130 |
Why?
|
| Alemtuzumab | 1 | 2018 | 89 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 236 | 0.130 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 509 | 0.130 |
Why?
|
| Inflammation | 3 | 2021 | 1489 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 172 | 0.130 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 81 | 0.130 |
Why?
|
| Arthritis | 2 | 2019 | 85 | 0.130 |
Why?
|
| Cell Differentiation | 3 | 2024 | 1928 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2026 | 2885 | 0.120 |
Why?
|
| Neonatal Screening | 3 | 2024 | 207 | 0.120 |
Why?
|
| rab27 GTP-Binding Proteins | 1 | 2016 | 5 | 0.120 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 215 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2019 | 227 | 0.120 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 61 | 0.120 |
Why?
|
| Diarrhea | 1 | 2017 | 301 | 0.120 |
Why?
|
| Interferon Type I | 2 | 2021 | 119 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 77 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 148 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 371 | 0.110 |
Why?
|
| Pedigree | 3 | 2020 | 1677 | 0.110 |
Why?
|
| Phenotype | 4 | 2026 | 4497 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 1211 | 0.100 |
Why?
|
| Lung Diseases | 2 | 2019 | 398 | 0.100 |
Why?
|
| Fontan Procedure | 1 | 2016 | 180 | 0.100 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2022 | 14 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 54 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2023 | 195 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 619 | 0.090 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 819 | 0.090 |
Why?
|
| Texas | 1 | 2020 | 3686 | 0.090 |
Why?
|
| BCG Vaccine | 1 | 2022 | 105 | 0.090 |
Why?
|
| Genetic Therapy | 2 | 2023 | 713 | 0.090 |
Why?
|
| Age of Onset | 2 | 2025 | 592 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2026 | 670 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1029 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2023 | 297 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1833 | 0.080 |
Why?
|
| Middle Aged | 6 | 2025 | 28601 | 0.080 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 362 | 0.080 |
Why?
|
| Aged | 5 | 2025 | 21025 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1559 | 0.070 |
Why?
|
| Survival Rate | 3 | 2020 | 2114 | 0.070 |
Why?
|
| Unrelated Donors | 2 | 2020 | 72 | 0.070 |
Why?
|
| Disease Management | 2 | 2025 | 558 | 0.070 |
Why?
|
| Contracture | 1 | 2019 | 26 | 0.070 |
Why?
|
| RNA | 1 | 2022 | 517 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 42 | 0.070 |
Why?
|
| Facies | 1 | 2019 | 157 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2019 | 152 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 67 | 0.070 |
Why?
|
| Mice | 2 | 2022 | 18301 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2019 | 82 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1621 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2023 | 1571 | 0.070 |
Why?
|
| Homeostasis | 1 | 2022 | 712 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 201 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12936 | 0.070 |
Why?
|
| Growth Disorders | 1 | 2019 | 181 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2596 | 0.060 |
Why?
|
| Viremia | 1 | 2018 | 130 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 405 | 0.060 |
Why?
|
| Registries | 2 | 2025 | 1634 | 0.060 |
Why?
|
| Allografts | 2 | 2017 | 220 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 775 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 335 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 301 | 0.060 |
Why?
|
| Monitoring, Immunologic | 1 | 2026 | 15 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 373 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 4886 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 386 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2019 | 406 | 0.060 |
Why?
|
| Microcephaly | 1 | 2019 | 347 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 633 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 905 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 786 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2019 | 388 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 343 | 0.060 |
Why?
|
| Pituitary Gland | 1 | 1995 | 74 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2026 | 192 | 0.050 |
Why?
|
| Cell Line | 2 | 2020 | 2552 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2022 | 17753 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5196 | 0.050 |
Why?
|
| NADPH Oxidases | 1 | 2025 | 109 | 0.050 |
Why?
|
| Pituitary Neoplasms | 1 | 1995 | 74 | 0.050 |
Why?
|
| Europe | 1 | 2025 | 365 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 1889 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 613 | 0.050 |
Why?
|
| Adenoma | 1 | 1995 | 144 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2026 | 639 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 65 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 981 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 963 | 0.050 |
Why?
|
| Meningioma | 1 | 1995 | 151 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 89 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 263 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1089 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2016 | 477 | 0.040 |
Why?
|
| Glycolipids | 1 | 2021 | 33 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 3360 | 0.040 |
Why?
|
| Wiskott-Aldrich Syndrome Protein Family | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 31 | 0.040 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 43 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2065 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 178 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 23 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 143 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4066 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 117 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2019 | 44 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1410 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 555 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 285 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 544 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 544 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 274 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1490 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 502 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 246 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 328 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 1010 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 209 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 66 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.030 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 33 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 333 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 314 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2018 | 111 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2017 | 3 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2017 | 26 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 128 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 241 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 200 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 371 | 0.030 |
Why?
|
| Pyrroles | 1 | 2018 | 188 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1216 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 223 | 0.030 |
Why?
|
| Piebaldism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Albinism | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 414 | 0.030 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2016 | 19 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1882 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 115 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2833 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 759 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2016 | 156 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 1306 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1155 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2016 | 193 | 0.030 |
Why?
|
| Family | 1 | 2018 | 589 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 2730 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 344 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2016 | 292 | 0.020 |
Why?
|
| Brain | 1 | 1995 | 3175 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 525 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2550 | 0.020 |
Why?
|
| Risk Factors | 2 | 2017 | 11074 | 0.020 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2016 | 400 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1652 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6459 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3819 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3061 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2825 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 1176 | 0.020 |
Why?
|
| Prolactin | 1 | 1995 | 142 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 743 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 1356 | 0.010 |
Why?
|